Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer
Open accessPublished version of a preprint
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Primary prostate cancer is generally treatable by androgen deprivation therapy, however, later recurrences of castrate-resistant prostate cancer (CRPC) that are more difficult to treat nearly always occur due to aberrant reactivation of the androgen receptor (AR). In this study, we report that CRPC cells are particularly sensitive to the growth-inhibitory effects of reengineered tricyclic sulfonamides, a class of molecules that activate the protein phosphatase PP2A, which inhibits multiple oncogenic signaling pathways. Treatment of CRPC cells with small-molecule activators of PP2A (SMAP) in vitro decreased cellular viability and clonogenicity and induced apoptosis. SMAP treatment also induced an array of significant changes in the phosphoproteome, including most notably dephosphorylation of full-length and truncated isoforms of the AR and downregulation of its regulatory kinases in a dose-dependent and time-dependent manner. In murine xenograft models of human CRPC, the potent compound SMAP-2 exhibited efficacy comparable with enzalutamide in inhibiting tumor formation. Overall, our results provide a preclinical proof of concept for the efficacy of SMAP in AR degradation and CRPC treatment. Significance: A novel class of small-molecule activators of the tumor suppressor PP2A, a serine/threonine phosphatase that inhibits many oncogenic signaling pathways, is shown to deregulate the phosphoproteome and to destabilize the androgen receptor in advanced prostate cancer. Cancer Res; 78(8); 2065–80. ©2018 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In line with the inability to stabilize AB56αC heterotrimers, these derivative compounds did not induce apoptosis in standard cell culture conditions and had a significantly reduced effect in low serum culture conditions as determined by GI50s (Fig. 4C; Fig S4A) (Kauko et al., 2018; McClinch et al., 2018; Sangodkar et al., 2017a; Tohmé et al., 2019).”
From Selective PP2A enhancement through biased heterotrimer stabilization (2020) · cites this paper as McClinch et al., 2018
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An automated method for finding molecular complexes in large protein interaction networks
Bader, G. D., & Hogue, C. W. (2003) · BMC Bioinformatics · doi:10.1186/1471-2105-4-2 · Cited by 6,072 · cited 2×
“Please refer to the original publication (26) for details on the formulas.”
BackgroundMethodIncreased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586 · cited 1×
“Studies in model systems, and in patients, have confirmed that the androgen receptor (AR) signaling axis remains a key therapeutic target in CRPC, and novel approaches to androgen biosynthesis inhibition and androgen receptor blockade have resulted in improved patient outcomes (1,2).”
BackgroundAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · cited 1×
“Studies in model systems, and in patients, have confirmed that the androgen receptor (AR) signaling axis remains a key therapeutic target in CRPC, and novel approaches to androgen biosynthesis inhibition and androgen receptor blockade have resulted in improved patient outcomes (1,2).”
BackgroundIntegrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,701 · cited 1×
“Chromosome 8q, including the MYC gene, is amplified in approximately 30% of human prostate cancers and c-MYC overexpression recapitulates human prostate carcinogenesis in genetically engineered mouse models (47,48).”
BackgroundHuman Protein Reference Database--2009 update
Keshava Prasad, T. S., Goel, R., Kandasamy, K., Keerthikumar, S., Kumar, S., Mathivanan, S., Telikicherla, D., Raju, R., Shafreen, B., Venugopal, A., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn892 · Cited by 3,234
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710 · cited 1×
“Moreover, the presence of AR-v7 in circulating tumor cells from metastatic CRPC patients correlates with clinical resistance to enzalutamide and abiraterone (34).”
BackgroundDevelopment of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Myc-driven murine prostate cancer shares molecular features with human prostate tumors
Ellwood-Yen, K., Graeber, T. G., Wongvipat, J., Iruela-Arispe, M. L., Zhang, J., Matusik, R., Thomas, G. V., & Sawyers, C. L. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00197-1 · Cited by 816 · cited 1×
“Chromosome 8q, including the MYC gene, is amplified in approximately 30% of human prostate cancers and c-MYC overexpression recapitulates human prostate carcinogenesis in genetically engineered mouse models (47,48).”
BackgroundWhy Do Hubs Tend to Be Essential in Protein Networks?
He, X., & Zhang, J. (2006) · PLoS Genetics · doi:10.1371/journal.pgen.0020088 · Cited by 701 · cited 1×
“These so-called “hub proteins” are often essential nodes of regulation within the cell (27).”
BackgroundARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
Clegg, N. J., Wongvipat, J., Joseph, J. D., Tran, C., Ouk, S., Dilhas, A., Chen, Y., Grillot, K., Bischoff, E. D., Cai, L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3948 · Cited by 662
Cited by
Selective PP2A enhancement through biased heterotrimer stabilization
Leonard, D., Huang, W., Izadmehr, S., O’Connor, C. M., Wiredja, D. D., Wang, Z., Zaware, N., Chen, Y., Schlatzer, D. M., Kiselar, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.038 · Cited by 176
“4C; Fig S4A) (Kauko et al., 2018; McClinch et al., 2018; Sangodkar et al., 2017a; Tohmé et al., 2019).”
Self-citationProtein phosphatases in the regulation of mitosis
Nilsson, J. (2019) · Journal of Cell Biology · doi:10.1083/jcb.201809138 · Cited by 112
“Given the central role of PP2A in several human diseases, the development of PP2A modulators that either increase or decrease its activity is being developed (Lai et al., 2018; McClinch et al., 2018).”
BackgroundProtein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration
Clark, A. R., & Ohlmeyer, M. H. J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.016 · Cited by 122
“lung cancer, prostate and pancreatic cancers (Allen-Petersen et al., 2019; Kauko et al., 2018; McClinch et al., 2018; Sangodkar et al., 2017; Tohme et al., 2019).”
Self-citationBrown, R. R., Nath, S., Lora, A., Samaha, G., Elgamal, Z., Kaiser, R., Taggart, C. C., Weldon, S., & Geraghty, P. M. (2020) · Respiratory Research · doi:10.1186/s12931-020-01381-5 · Cited by 109
PP2A holoenzymes, substrate specificity driving cellular functions and deregulation in cancer
(2019) · Advances in Cancer Research · doi:10.1016/bs.acr.2019.03.009 · Cited by 93
Metadata
- Authors
- McClinch, K., Avelar, R. A., Callejas, D., Izadmehr, S., Wiredja, D., Perl, A., Sangodkar, J., Kastrinsky, D. B., Schlatzer, D., Cooper, M., Kiselar, J., Stachnik, A., Yao, S., Hoon, D., McQuaid, D., Zaware, N., Gong, Y., Brautigan, D. L., Plymate, S. R., Sprenger, C. C. T., Oh, W. K., Levine, A. C., Kirschenbaum, A., Sfakianos, J. P., Sears, R., DiFeo, A., Ioannou, Y., Ohlmeyer, M., Narla, G., & Galsky, M. D.
- Affiliations
- Tisch Cancer Institute (US)
- Case Western Reserve University (US)
- Icahn School of Medicine at Mount Sinai (US)
- 6Department of Medicine, Division of Endocrine, Diabetes and Bone Diseases, Icahn School of Medicine at Mount Sinai, New York, New York.
- University of Virginia (US)
- University of Washington (US)
- Oregon Health & Science University (US)
- Case Comprehensive Cancer Center (US)
- Corresponding author
- Narla, Goutham
- Galsky, Matthew D.
- ORCID
- Avelar, Rita A.
- Izadmehr, Sudeh
- Wiredja, Danica
- Perl, Abbey
- Schlatzer, Daniela
- Kiselar, Janna
- McQuaid, Daniel
- Zaware, Nilesh
- Brautigan, David L.
- Plymate, Stephen R.
- Sprenger, Cynthia C.T.
- Oh, William K.
- Levine, Alice C.
- Sfakianos, John P.
- Sears, Rosalie
- DiFeo, Analisa
- Ioannou, Yiannis
- Ohlmeyer, Michael
- Narla, Goutham
- Galsky, Matthew D.
- Venue
- Cancer Research
- Published
- 2018-04-12
- Volume
- 78
- Issue
- 8
- Pages
- 2065-2080
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC5899650
- OpenAlex
- W2797816307
- Cited by
- 78
- References
- 49
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 7 · 2023: 11 · 2022: 5 · 2021: 8 · 2020: 13 · 2019: 15 · 2018: 6
- FWCI
- 7.91
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- HHS | NIH | National Cancer Institute (NCI) (1R01CA181654-01A1)
- Prostate Cancer Foundation (PCF) (Young Investigator Award)
- U.S. Department of Defense (DOD) (W81XWH-15-1-0596)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- castration-resistant prostate cancer, protein phosphatase 2A, PP2A activators, androgen receptor degradation, phosphoproteome, apoptosis, enzalutamide, tumor suppressor phosphatase
- MeSH terms
- Protein Phosphatase 2C, Animals, Humans, Male, Phosphoproteins, Receptors, Androgen, RNA, Messenger, Mice, SCID, Enzyme Activators, Proteomics, Cell Line, Tumor, Mice, Small Molecule Libraries, Prostatic Neoplasms, Castration-Resistant, Heterografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-17-0123
- The paper
- McClinch, K., Avelar, R. A., Callejas, D., Izadmehr, S., Wiredja, D., Perl, A., Sangodkar, J., Kastrinsky, D. B., Schlatzer, D., Cooper, M., Kiselar, J., Stachnik, A., Yao, S., Hoon, D., McQuaid, D., Zaware, N., Gong, Y., Brautigan, D. L., Plymate, S. R., . . . Galsky, M. D. (2018). Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-17-0123
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.